114 related articles for article (PubMed ID: 8287204)
1. The use of octreotide in bowel obstruction.
Mercadante S
Palliat Med; 1993; 7(1):78. PubMed ID: 8287204
[No Abstract] [Full Text] [Related]
2. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
[TBL] [Abstract][Full Text] [Related]
3. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
4. The role of octreotide in malignant bowel obstruction.
Krammer LM
Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
[No Abstract] [Full Text] [Related]
5. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
Tanimura K; Onda S; Mitsunobu M
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
[TBL] [Abstract][Full Text] [Related]
6. How to use octreotide for malignant bowel obstruction.
Ripamonti C; Mercadante S
J Support Oncol; 2004; 2(4):357-64. PubMed ID: 15357519
[No Abstract] [Full Text] [Related]
7. The challenge of treating malignant bowel obstruction.
J Support Oncol; 2006 Feb; 4(2):83-4. PubMed ID: 16499129
[No Abstract] [Full Text] [Related]
8. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
Weber C; Zulian GB
Am J Hosp Palliat Care; 2009; 26(2):84-8. PubMed ID: 19088264
[TBL] [Abstract][Full Text] [Related]
9. The palliative effects of octreotide in malignant disease.
Dean A; Bridge D; Lickiss JN
Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613
[TBL] [Abstract][Full Text] [Related]
10. Scopolamine butylbromide plus octreotide in unresponsive bowel obstruction.
Mercadante S
J Pain Symptom Manage; 1998 Nov; 16(5):278-80. PubMed ID: 9846021
[No Abstract] [Full Text] [Related]
11. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients.
Mercadante S; Maddaloni S
J Pain Symptom Manage; 1992 Nov; 7(8):496-8. PubMed ID: 1283750
[No Abstract] [Full Text] [Related]
12. Palliation of malignant intestinal obstruction using octreotide.
Khoo D; Hall E; Motson R; Riley J; Denman K; Waxman J
Eur J Cancer; 1994; 30A(1):28-30. PubMed ID: 7511400
[TBL] [Abstract][Full Text] [Related]
13. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
[No Abstract] [Full Text] [Related]
14. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
15. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
Watanabe H; Inoue Y; Uchida K; Okugawa Y; Hiro J; Ojima E; Kobayashi M; Miki C; Kusunoki M
J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
[TBL] [Abstract][Full Text] [Related]
16. Octreotide acetate administration for malignant bowel obstruction induces severe bradycardia in patients with terminal stage cancer: two case reports.
Kubota K; Hasumi Y; Numata A; Tukazaki T; Horie K; Hashimoto K; Yokota H
J Palliat Med; 2013 Jun; 16(6):596-7. PubMed ID: 23600413
[No Abstract] [Full Text] [Related]
17. Management of treatment-related intermittent partial small bowel obstruction: the use of octreotide.
Myers J; Tamber A; Farhadian M
J Pain Symptom Manage; 2010 Apr; 39(4):e1-3. PubMed ID: 20153136
[No Abstract] [Full Text] [Related]
18. Octreotide may prevent definitive intestinal obstruction.
Mercadante S; Kargar J; Nicolosi G
J Pain Symptom Manage; 1997 Jun; 13(6):352-5. PubMed ID: 9204656
[TBL] [Abstract][Full Text] [Related]
19. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
Matulonis UA; Seiden MV; Roche M; Krasner C; Fuller AF; Atkinson T; Kornblith A; Penson R
J Pain Symptom Manage; 2005 Dec; 30(6):563-9. PubMed ID: 16376743
[TBL] [Abstract][Full Text] [Related]
20. Aggressive pharmacological treatment for reversing malignant bowel obstruction.
Mercadante S; Ferrera P; Villari P; Marrazzo A
J Pain Symptom Manage; 2004 Oct; 28(4):412-6. PubMed ID: 15471659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
